Options
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Journal
The Lancet
Journal Volume
389
Journal Issue
10088
Pages
2492-2502
Date Issued
2017
Author(s)
El-Khoueiry A.B.
Sangro B.
Yau T.
Crocenzi T.S.
Kudo M.
Kim T.-Y.
Choo S.-P.
Trojan J.
Welling T.H.
3rd, Meyer T.
Kang Y.-K.
Yeo W.
Chopra A.
Anderson J.
dela Cruz C.
Lang L.
Neely J.
Tang H.
Dastani H.B.
Melero I.
Publisher
Lancet Publishing Group
Type
journal article